NCT05074693

Brief Summary

The proposed research focuses on evaluating the mobile application, Easing Anxiety Sensitivity for Everyone (EASE), to improve overall public health that concerns risks and mental health status during the coronavirus disease of 2019 (COVID-19) pandemic and to minimize the existing health disparities among Black, Hispanic and Latino, and American Indian (BLAI) individuals during this time. EASE provides COVID-19 symptom monitoring, exposure management skills, and psychoeducation on stress and it's impact on infection and disease susceptibility. This study aims to compare the effect of EASE to an empirical measurement of standard-of-care digital intervention and to identify the effective mechanisms in EASE.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
822

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2021

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 2, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 12, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

December 20, 2021

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 26, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 26, 2024

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

September 24, 2025

Completed
Last Updated

September 24, 2025

Status Verified

September 1, 2025

Enrollment Period

2.1 years

First QC Date

October 2, 2021

Results QC Date

July 7, 2025

Last Update Submit

September 4, 2025

Conditions

Keywords

COVID-19Health DisparitiesMobile Health

Outcome Measures

Primary Outcomes (3)

  • Everyday Impairment

    Changes in reported anxiety and depression related impairment experienced in major life sectors (work performance, household maintenance, social interactions, relationships) as measured by study developed items from Baseline to follow-up assessments. This measure was created by the study team and was 4 items rated from 1 (Strongly disagree) to 5 (Strongly agree). The scale is summed for a total score with ranges from 4 to 25, with higher scores indicating greater everyday impairment.

    From Baseline to 6-Months

  • Anxiety

    Change from Screener in anxiety on the 5-item Overall Anxiety Severity and Impairment Scale (OASIS) at follow-up appointments. The OASIS is made up of 5 items rated on a scale from 0 to 4. The OASIS is summed for a total score, with a range from 0 to 25, with higher scores indicating higher anxiety severity and impairment.

    From Screener to 6-Months

  • Depression

    Change from Screener in depression on the 5-item Overall Depression Severity and Impairment Scale (ODSIS) at subsequent follow-up appointments. The ODSIS is made up of 5 items rated on a scale from 0 to 4. The ODSIS is summed for a total score, with a range from 0 to 25, with higher scores indicating higher depression severity and impairment.

    From Screener to 6-Month

Secondary Outcomes (8)

  • Perceived Discrimination

    From Baseline to end of study, up to 6 months.

  • Racial Bias/Discrimination

    From Baseline to end of study, up to 6 months.

  • Perceive Social Support

    From Baseline to end of study, up to 6 months.

  • Subjective Social Status

    From Baseline to end of study, up to 6 months.

  • Anxiety Sensitivity

    Baseline to end of study, up to 6 months.

  • +3 more secondary outcomes

Study Arms (2)

EASE App

EXPERIMENTAL

EASE is a intervention designed to address anxiety and depression symptoms in its users through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress.

Other: EASE app

INSIGHT (Control) APP

OTHER

The Insight app provides users with educational videos on mindfulness and meditation techniques.

Other: INSIGHT (Control) App

Interventions

EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.

EASE App

A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a "Report Distress" feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos.

INSIGHT (Control) APP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 18 years of age
  • Self-identify as Black, Latinx, American Indian, or NLW
  • Clinically significant anxiety and/or depressive symptoms as evinced by a score of 8 or higher on the Overall Anxiety Severity and Impairment Scale (OASIS) and/or Overall Depression Severity and Impairment Scale (ODSIS)
  • Reside in Texas or Oklahoma
  • Willing/able to complete EMAs on study provided or personal smartphone for 6-month study period
  • Willing and able to complete the 3- and 6-month follow-up assessments via the app and over the phone (i.e., qualitative interview)
  • Score ≥ 4 on the REALM-Short Form indicating \> 6th grade English literacy level (needed to complete EMAs)

You may not qualify if:

  • Not fluent in English
  • Lifetime or significant cognitive impairment
  • Identifying as a race/ethnicity for which the corresponding study cell has been filled

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

TSET Health Promotion Research Center

Oklahoma City, Oklahoma, 73104, United States

Location

RESTORE Laboratory: Research on Emotion, Substance Use Treatment Outcomes, Rehabilitation, and Empowerment

Houston, Texas, 77204, United States

Location

Related Publications (2)

  • Rhudy JL, Kell PA, Shadlow JO, Lowe TS, Stephens LD, Zvolensky MJ, Garey L, Kendzor DE, Businelle MS. Assessing racial/ethnic differences in sleep-pain relationships using intensive longitudinal modeling among Native Americans. Sleep. 2026 Jan 13;49(1):zsaf216. doi: 10.1093/sleep/zsaf216.

  • Garey L, Zvolensky MJ, Gallagher MW, Vujanovic A, Kendzor DE, Stephens L, Cheney MK, Cole AB, Kezbers K, Matoska CT, Robison J, Montgomery A, Zappi CV, Businelle MS. A Smartphone-Based Intervention for Anxiety and Depression in Racially and Ethnically Diverse Adults (EASE): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2022 Dec 5;11(12):e40713. doi: 10.2196/40713.

MeSH Terms

Conditions

COVID-19

Interventions

Amyloid

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Multiprotein ComplexesMacromolecular SubstancesProteinsAmino Acids, Peptides, and Proteins

Results Point of Contact

Title
Michael Zvolensky, Ph.D.
Organization
University of Houston

Study Officials

  • Michael Zvolensky, Ph.D.

    University of Houston

    PRINCIPAL INVESTIGATOR
  • Michael Businelle, Ph.D.

    University of Oklahoma Health Sciences

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Hugh Roy and Lillie Cranz Cullen Distinguished University Professor

Study Record Dates

First Submitted

October 2, 2021

First Posted

October 12, 2021

Study Start

December 20, 2021

Primary Completion

January 26, 2024

Study Completion

January 26, 2024

Last Updated

September 24, 2025

Results First Posted

September 24, 2025

Record last verified: 2025-09

Locations